Home

Awaiting Liftoff…Catalyst List

Jumping the gun by a couple days here, but January has been a very good month for stocks. The average stock in TW's universe...

Trading Update, January 27th 2023

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Movano Health Prices $6.5 Million Public Offering

TW's Take: positive to get some financing done which should allow the company to achieve key milestones without additional financing. The biggest risk to...

INmune in DMD…Yet Another Indication of Future Success

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne...

TW's Take: exciting news as the "wonder drug" that is XPro demonstrates exciting data in yet another major, untreated disease.  Boca Raton, Florida, Jan. 25,...

Looking for 3-5X This Year? These Two Jackpot Stocks Offer That Potential

In 2022, interest rates killed micro-cap. This year, with increased expectations of a recession and an associated end of rate increases, the smaller stocks...

Spectra7 Announces Preliminary Fourth Quarter and Annual Financial Results for the Year Ended December...

TW's Take: Glad to see that the company will be approaching, if not achieving, EBITDA positive operations very soon. Stabilizing the cash flows and...

enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer

TW's Take: our view on NVNO remains that the product will gain approval and substantial sales, but likely remains off investors' radar screens until...

Notes for Premium Subscribers

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate...

TW's Take: continued execution as they move this incredibly promising drug into human trials sometime in the not too distant future. LTRN still trading...

The January Halftime Report

It has been a great start to 2023, particularly for smaller, growth stocks. The most likely explanation for this is investor expectations regarding inflation...

The 2023 Game Plan

Entering 2023, I'm fairly confident that everyone who subscribes to TW's service knows my thoughts on the overall market. In a nutshell, I believe...

Spectra7, ACON, and Mo-Link to Demonstrate Thunderbolt 4 Active Copper Cables at CES 2023

TW's Take: when SPVNF finally starts ramping sales of active copper cables into data centers, the stock should launch. LAS VEGAS, Jan. 5, 2023 /PRNewswire/ -- (TSXV:...

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

TW's Take: this is a great step, bringing in house the expertise needed to take products through clinical development and commercialization or partnering. FORT WORTH,...

For The TW Portfolio, Our FATE Awaits

This past week, thanks to a big move on Friday, saw the markets start the new year on a positive note. Investors increasingly believe...

IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals

TW's Take: Gamma-Delta T-Cells is a very hot space and IN8bio is proving to be a leader here. The stock is dramatically undervalued relative...

IN8bio to Present at Biotech Showcase 2023 in San Francisco

TW's Take: expecting good news from their GBM program this coming week before they start presenting to investors in San Francisco. NEW YORK, Jan. 03,...

The Light at the End of the Tunnel

In the hills just west of Charlottesville lies the Crozet Tunnel. Built in the mid 1800's, it was a major supply route in the...

Trading Thoughts As We Prepare To Swap Out The Calendar

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely for Women

TW's Take: if they can get FDA approved, will be a key differentiation versus the competition. Movano is significantly undervalued relative to peers and...

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.